therapeutic parasite reduction or removal of harmful materials · asfa guideline: rationale for...
TRANSCRIPT
Therapeutic Parasite Reduction or Removal of Harmful Materials
Yanyun Wu, MD, PhD
Chief Medical Officer
Conflict of Interest
• None
Puget Sound Blood Center is now Bloodworks Northwest After 70 years Puget Sound Blood Center is changing our name!
November 20, 2015, ASFA regional Meeting
Cases Case 1
A 53-year-old male resident of Connecticut was admitted to ER in July. He recently had a week-long camping trip.
He presented with high fevers (40 C), shaking chill, weakness, and fatigue. He had severe hemolytic anemia (Hct of 21%)/pancytopenia (platelet count of 33K), with signs of disseminated intravascular coagulation, acute renal failure, and respiratory failure. He was intubated and transferred to ICU overnight.
There was no history of splenectomy or immunodeficiency.
Cases Case 2 • 60 year old woman with a prolonged hospital stay
(7 months) due to multiple medical and surgical issues.
• For the last week, patient has been spiking temp of 39 to 40 C.
• Significant DAT negative hemolytic anemia (Hct of 27%)
• She received transfusion of 4 units RBC 4 weeks ago. And she has a history of splenectomy
Kyle Noskoviak, M.D., and Elizabeth Broome, M.D. N Engl J Med 2008; 358:e19April 24, 2008DOI: 10.1056/NEJMicm070903
N Engl J Med 2012;366:2397-407.
Human babesiosis summary
Causative pathogen: protozoal parasite in phylum Apicomplexa
Target tissue: red blood cells
Transmission:
Ixodid ticks (Ixodes scapularis)
Blood transfusion
Perinatal/transplacental
Diagnosis: epidemiology, symptoms, microscopy, PCR, antibody
Treatment: atovaquone/azithromycin or clindamycin/quinine, exchange transfusion
Courtesy of Dr. Peter Krause, Yale
Babesia species causing human infection
US
• B. microti
• B. duncani
• B. divergens-like
Vannier and Krause, N. Engl. J. Med., 2012
Courtesy of Dr. Peter Krause, Yale
Europe • B. divergens • B. venatorum • B. microti
Asia • B. microti-like • K01
Year
Nu
mb
er c
ases
Babesiosis in the US 1986-2011
0
100
200
300
400
500
600
700
800
900
1000
1100
86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11
Courtesy of Dr. Peter Krause, Yale
One of the most common infections of free-living animals worldwide and an emerging infection in humans
Human babesiosis
• Require both a competent vertebrate and nonvertebrate host to maintain transmission cycles
• Transmitted by ixodid ticks to their vertebrate hosts
• Replicate in the vertebrate hosts’ red blood cells
Vannier E and Krause PJ. New Engl J Med, 2012
Transmission of Babesia microti by the Ixodes scapularis Tick
Courtesy of Dr. Peter Krause, Yale
Trophozoite
Merozoite
Pre-gametocyte
Gametes fuse
in the gut
Zygote enters
gut epithelium
Sporoblasts/Sporozoites
in salivary glands
Life cycle of Babesia microti
Courtesy of Dr. Peter Krause, Yale
Life cycle of Babesia microti
Babesiosis
Babesiosis clinical manifestations
1. Asymptomatic infection 2. Viral-like illness Fever, chills, sweats, headache, fatigue 3. Severe illness and death (5-21%) >50, asplenic, HIV, malignancy, blood transfusion recipients • Persistent, relapsing illness HIV/AIDS, malignancy, asplenic, immunosuppressive drugs • The incubation period is usually 1–3 weeks
Courtesy of Dr. Peter Krause, Yale
Babesiosis: persistent parasitemia
(DNA)
Krause, Spielman, Telford, et al., New Engl J Med, 1998
Courtesy of Dr. Peter Krause, Yale
Transfusion transmitted babesiosis
• Symptoms delayed as long as 1 week to 6 months after transfusion
• Symptoms similar to those of tick-transmitted disease but often more severe because blood recipients are often immunocompromised
• Mortality rate ranges from about 10% to 21%
Courtesy of Dr. Peter Krause, Yale
Babesiosis in highly immunocompromised patients
Clinical characteristic Cases
(n=14)
Controls
(n=46)
P value
Median number of antibiotic courses
(range)
4 (2-10) 1 <0.001
Median number hospital admissions
(range)
1.5 (0-4) 1 (0-1) <0.001
Median weeks of therapy (range) 13 (4-
102)
1 (0.5-1.5) <0.001
Number with complications (percent) 8 (57) 2 (4) <0.001
Number with fatal infection (percent) 3 (21) 0 <0.02
Krause, Gewurz, Hill, et al. Clin Inf Dis, 2008
Courtesy of Dr. Peter Krause, Yale
Babesiosis in highly immunocompromised patients • People suffering from broad-based immunosuppression are at risk of persistent relapsing Babesia microti infection
• Adaptive immunity (B and T cell) are important for resolution of infection
• These patients generally require anti-babesial therapy for at least 6 weeks, including 2 weeks after babesia are no longer detected on blood smear
Courtesy of Dr. Peter Krause, Yale
General approach to diagnosis
Epidemiology
Medical history
Physical examination
Laboratory testing
Courtesy of Dr. Peter Krause, Yale
Specific laboratory diagnosis
Microbial detection
Blood smear
Polymerase chain reaction
Small rodent inoculation
Antibody detection
IFA
Immunoblot
ELISA
Courtesy of Dr. Peter Krause, Yale
Diagnostic algorithm for babesiosis
Cunha et al, Clinical Infectious Diseases® 2015;60(5):827–9
Diagnosis
Cunha et al, Clinical Infectious Diseases® 2015;60(5):827–9
Treatment of babesiosis caused by Babesia microti
Mild illness Atovaquone (PO) + azithromycin (PO) Administration for 7-10 days
Severe illness Clindamycin (IV or PO) + quinine (PO) Administration for 7-10 days
Persistent or relapsing illness Atovaquone (PO) + azithromycin (PO) OR Clindamycin (IV or PO) + quinine (PO) Administration for at least 6 wks, including 2 wks after parasites are no longer detected on blood smear
Courtesy of Dr. Peter Krause, Yale
Babesiosis
Babesiosis
• What are we removing?
• What are we adding back?
• Have we changed patient outcome?
• Give me the proof!
• Show me the data!
Babesiosis
Readings: 1. Dorman et al, TRANSFUSION Volume 40, March 2000 2. Spaete et al, Journal of Clinical Apheresis 24:97–105 (2009)
Babesiosis
Dorman et al, TRANSFUSION Volume 40, March 2000
Dorman et al, TRANSFUSION Volume 40, March 2000
Dorman et al, TRANSFUSION Volume 40, March 2000
Dorman et al, TRANSFUSION Volume 40, March 2000
Dorman et al, TRANSFUSION Volume 40, March 2000
Summary
• 15 males (63%)
• The mean age: 56 years (SD 16; range, 25–77)
• The mean pretransfusion hemoglobin: 8.1 g/dl (SD 2.5; range, 4.7–13.7).
• The mean preRCE or preWBE level of parasitemia was 18% (SD 14; range, 1.6–60)
• The mean postExchange level of parasitemia was 3.6% (SD 3.8; range, 0.1–13.8) with a median of 2%
• Fifteen (63%) of the 24 patients were asplenic
• Two of four who died were asplenic, and a third was reported to have necrotic splenic lesions on postmortem exam
Babesiosis
Spaete J et al, J Clin Apher. 2009;24(3):97-105.
Babesiosis
Babesiosis
Harmful Materials:
• Parasite: from RBC only?
• Cytokine?
• Free Heme
• Others?
ASFA guideline: Rationale for therapeutic apheresis
1. First, it helps to lower the level of parasitemia by physically removing the infected RBCs from the blood stream and replacing them with noninfected RBCs. Because babesia organisms do not have an exo-erthrocytic phase, removal of RBC-associated parasites might be very effective.
2. Second, by removal of rigid infected cells, RBC exchange could decrease obstruction in the microcirculation and tissue hypoxia caused by adherence of RBCs to vascular endothelium.
3. Finally, the hemolytic process produces vasoactive compounds, including a variety of cytokines (including INF-g, TNF-a, IL-1, IL-6), nitric oxide and thromboplastin substances, which can promote renal failure and DIC. RBC exchange may help to remove the proinflammatory cytokines.
Babesiosis
Shaio MF et al. Am J Trop Med Hyg. (1998)
Babesiosis
Shaio MF et al. Am J Trop Med Hyg. (1998)
Krause PJ, et al. Trends in Parasitology, 2007;23:605-610.
Courtesy of Dr. Peter Krause, Yale
Pathogenesis
Excessive erythrocyte cytoadherence: Additionally, erythrocytes infected with some babesia species
undergo membrane changes that cause these erythrocytes to adhere to the vascular endothelium Excessive pro-inflammatory cytokine production During a babesia infection, inflammatory cytokines including tumor
necrosis factor a (TNF-a) and interleukin 6, and adhesion molecules such as Eselectin, intracellular adhesion molecule 1 and vascular-cell adhesion molecule 1 are upregulated
While moderate synthesis of these factors may be protective,
excessive upregulation may result in severe babesiosis
Krause PJ, Daily J, Telford SR, et al. Trends Parasitol, 2007
Sloan et al, Journal of Clinical Apheresis 00:00–00 (2014)
• Cytoadherence most thoroughly studied in B. bovis infection
• Cattle infected by B. bovis die from encephalopathy as erythrocytes obstruct brain blood vessels.
• B. bovis encephalopathy similar to human P. falciparum cerebral malaria
• Cytoadherence is beneficial for the parasite as it delays or prevents filtering/removal of infected RBCs by the spleen.
Erythrocyte cytoadherence
Courtesy of Dr. Peter Krause, Yale
Pro-inflammatory cytokines
• Severe disease occurs without erythrocyte cytoadherence for B. microti, suggesting other pathogenic mechanisms.
• Pro-inflammatory cytokines such as TNF-α and IFN-γ protect the host against B. microti infection but if produced in excess may cause severe symptoms and complications.
Courtesy of Dr. Peter Krause, Yale
Babesiosis
• When do you start or stop?
• How to exchange?
• Patient consent?
• Others?
Babesiosis
Ziggy Vote
1. Agree with ASFA Category? 2. More Study?
a. RCT? b. CT? c. Registry?
3. What kind of exchange? a. RBC b. RBC+ Plasma? c. Whole Blood?